Over the weekend the Times carried an article about how the market in unlicensed medicines had grown
Personally I think this could be either a positive or negative depending in what happens to this stock..
Could explain to where we are now. This will either plumet or rocket during the next few months . Only my opinion..S dyor.. That's of course if there are Pi investors in this which is looking less and less likely as the days pass
Why wasn't he made to stay... Either they realised that he would be an overpaid director doing practically nothing.. Alternatively he realised that he made a big mistake either internally or selling QP out before they could show what they were capable of.
I,d be interested in peoples views, but this being a bizaar share as no one seems to air any opinions on this either way..
INMO.. This will either be a stellar share or the next p...pck.. So DYOR
Looks like this was over priced when they stitched up Qp shareholders.
An I on my own thinking that the CEO together with his board only looked after themselves..
What a surprise.
I am little baffled as to what value he added.. A ten year old would have able to work out that closing a loss making devision to only focus on the profitable was the way forward.. He evidently could not add any value after doing the obvious.. So sold out when basically he had nothing to do and not being capable of taking the company forward.
the cash element is below what I paid so I can use the loss against other capital gains. Its a calculation I still need to do whether its now or in the future, so having the base cost is still necessary to me. Anyone know what that base cost is please?
I want to work out the base cost and CGT situation on the QP takeover. Im clear that receiving part cash for the takeover constitutes a disposal for CGT purposes, but how much do I apportion to the cash and how much to the new Clinigen shares? what percentage?
And secondly is the value attributed to the Clinigen shares received, the closing price of Clinigen shares on 1 Nov when the deal completed?
There may be good reasons for Glass selling all his shares but seems a little unusual and a bit unsettling. SP on the slide in last few days, not sure if this contributed.
Several board changes announced of late, but Mr. Glass not one of them.
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the global pharmaceutical and services group, announces that it was notified on 30 October 2017 that the following transaction took place on 30 October 2017.
Steve Glass, Chief Commercial Officer, sold 17,360 ordinary shares of 0.1 pence each in the Company at a price of 1131 pence per share.
Following this transaction, Mr Glass no longer holds any ordinary shares in the Company.
With the price increasing toward the £11 recently due to the purchasing of Quantum Pharma I have decided to sell my shares today after several years of holding.
I feel the company may now be overvalued for the time being, it has around £1 per shares worth of tangible assets, and £2 worth of equity within the company. Revenue only increased 7 % last year, although gross profit did increase 22%.
This is not to say that the company is in excellent shape financially, and the management are obviously keen to expand its 'empire' with the prospect of adding Quantum Pharma.
This is a good buy with obvious parallels to Clinigens own business, but Quantum Pharma did state a loss with write downs on deadwood business last year, and I still question the current business value with Quantum Pharma figures in the mix.
Quantum Pharma plc is a growing manufacturer, supplier and service provider within the pharmaceutical sector. It is a market leader (in terms of its size or its service offering) in each of the niche markets in which it operates. Its customers include pharmaceutical wholesalers and retail pharmacies, hospitals, pharmaceutical companies, care homes and home care operators. Quantum's core business is the manufacture, procurement and supply to major UK pharmacy chains, wholesalers and hospitals of Specials and Special Obtains. Specials are medicines which are not licensed for general manufacture, which are prescribed for a specific patient need and which are manufactured or procured under an MHRA licence. Special Obtains are medicines and medicinal products that are difficult for pharmacies to source from a mainline pharmaceutical wholesaler. Quantum has a range of around 22,000 Special and Special Obtain products. It regularly services around 6,500 pharmacies and over 240 hospital accounts across the UK. Through acquisition and investment, Quantum has expanded into additional markets, including aseptic compounding and supplying home care and care home patients. The Group has gained access to overseas markets via U L Medicines Limited, significant product development and licensing expertise through Colonis Pharma Limited and has entered into a joint venture in the Republic of Ireland.
"Daniel Nickols, manager of the Old Mutual UK Smaller Companies fund, tells Marina Gerner which stocks he has been buying, selling and holding recently.Daniel Nickols has been the lead manager of FUND:A3I9:Old Mutual UK Smaller Companies since ..."
On 30 december Innocoll Holdings announced that it has received a Refusal to File letter from the U.S. Food and Drug Administration for Xaracoll, the company's product candidate for the treatment of postsurgical pain. Xaracoll belongs to the Bupivacaine family. Clinigen just signed an agreement for the distribution of BioQ's Ropivacaine which is also a post-operative pain management product. Bad news for Innocoll is probably good news for BIOQ pharma and indirectly also positive for Clinigen.
Excellent results out today and I think justify the 11% share price increase at the time of writing. The results have also been achieved whilst lowering debt so they are real. I think leadership of a niche within the pharmaceutical sector is a very nice place to be, and I would congratulate the board and management on this strategy.
I can't help but think that producing a drug in a bag instead of a bottle is not exactly major news, particularly as no relevant financial figures are given! Still, better to provide too much information than too little.
<b>Clinigen Group PLC 57.4% Potential Upside Indicated by Peel Hunt
Posted by: Katherine Hargreaves 2nd March 2016</b>
Clinigen Group PLC using EPIC/TICKER code LON:CLIN had its stock rating noted as Reiterates with the recommendation being set at BUY this morning by analysts at Peel Hunt. Clinigen Group PLC are listed in the Health Care sector within AIM. Peel Hunt have set their target price at 1000 GBX on its stock. This is indicating the analyst believes there is a potential upside of 57.4% from the opening price of 635.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 3.77805799999999 points and decreased 45 points respectively.
Clinigen Group PLC LON:CLIN has a 50 day moving average of 652.97 GBX and a 200 day moving average of 670.64 GBX. The 1 year high for the share price is 773.5 GBX while the 52 week low for the share price is 495 GBX. There are currently 114,740,899 shares in issue with the average daily volume traded being 383,240. Market capitalisation for LON:CLIN is £731,358,378 GBP.
Clinigen Group PLC is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Clinigen unveils latest deal alongside strong set of interims
07:29 02 Mar 2016</b>
The company's results reveal a company in rude health - and one still on the acquisition trial.
Clinigen unveils latest deal alongside strong set of interims
Clinigen seems to have found the formula for financial success.
The ambitious specialty pharma group Clinigen (LON:CLIN) revealed the positive financial impact of a recent acquisitions and tie-ups as it unveiled its interim results.
Alongside in a separate announcement it said it had bulked up its medicine cabinet with the acquisition of a product called Totect, which is used in cancer care.
The terms of the deal with American firm Biocodex were not disclosed, although Clinigen said it is making an upfront payment along with further instalments over the next 12 months.
Totect, which is also known as dexrazoxane, reverses the toxic effects of anthracycline, which is used in chemotherapy. It used to repair damage where the cancer drug accidentally leaks outside the vein and into the surrounding tissue.
The acquisition, together with Clinigens purchase of Savene in 2014, gives the company a complete global footprint in this specialist area of medicine.
David Moran, managing director of Clinigens speciality pharmaceuticals business, said the Totect was a natural target for us as we continue to focus on acquiring niche, hospital-only therapies.
Separately, the group unveiled its first-half results, which showed a more than doubling of revenues to £157.1mln and a 74% rise in operating profits to £23.5mln.
Clinigens cash balance grew by 96% compared with a year earlier to £22.1mln, while the interim dividend will be boosted by 18% to 1.3p a share.
The results statement revealed the company is starting to feel the benefits from its £225mln purchase of Idis, a specialist in the ethical supply on unlicensed medicines, and Link Healthcare, which has become part of Clinigens managed access division.
Its global footprint will expand further thanks to a global alliance with NASDAQ-listed Cumberland Pharmaceuticals.
Todays results release showed all the commercial and most of the operational integration is complete at Idis.
The firm also told investors that a revitalisation of its newer products had driven the strong performance of its speciality pharma division.
The company is positioned for a good second half, it added.
"We have made significant progress towards meeting our strategic objectives as a result of the acquisitions of Idis in April and Link Healthcare in October last year, and our alliance with US Specialty Pharmaceuticals company, Cumberland Pharmaceuticals, said chief executive Peter George.
"We are firmly established as the global market leader in the management and supply of unlicensed and clinical trial medicines. We now have the platform to realise considerable organic growth opportunities across a number of markets.
Clinigen is essentially four different companies under one roof, although there are synergies between the component parts.
Clinical trial services essentially does what it says on the tin it supplies drugs for clinical trials.
There is an ethical dimension to Clinigen in that it provides managed access and global access programmes for drugs, so it might find and distribute medicines for compassionate use.
Global access allows a medicine not yet commercially available, or is experiencing temporary supply problems, to be distributed to those in need.
Finally, Clinigen has a niche drugs arm for products that dont fit into the portfolio of mainstream pharmaceutical companies. This business provided the strongest growth in the first half.
Pharmaceutical company Clinigen (CLINC) has had a transformative 12 months thanks to acquisitions and new agreements.
Peel Hunt analyst Charles Hall retained his buy recommendation and target price of £10.00 on the shares, which fell 5.7% to 598.6p yesterday.
The last 12 months has been transformative with the acquisitions of Idis and Link as well as the agreement with Cumberland, he said.
The benefits do not show through in H1, but will become increasingly apparent. The company has had a solid H1 with pro forma gross profit +4%, with the prospect of a stronger H2 due to the timing of shipments of [herpes treatment] Foscavir as well as projects in clinical trial supply services.
In addition, the pipeline in managed access is descried as excellent and should start to be delivered in H2.Hall added that the company was well set to develop its global footprint.
Unsurprisingly during a period of substantial change the rate of organic growth has slowed. However, there are clear signs of a stronger performance in H2 and the rate of new business wins is encouraging. Clinigen is well positioned to deliver strong growth and is on an attractive rating of 15.8x price earnings to June 2017. "
Thanks for the response , I got in to this a few years back at around 230p so not too phased by the retrace , I had missed the director sells (to busy playing beach bum in Thailand!) hard to know at the moment whether big sells are company specific or people looking at Schiller PE ratios and backing away from the markets
The 3rd party interest has always been my thought/hope on this one
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.